SI-BONE, Inc. Stock

Equities

SIBN

US8257041090

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 02:21:58 2024-05-28 pm EDT 5-day change 1st Jan Change
13.69 USD +1.03% Intraday chart for SI-BONE, Inc. -2.63% -34.83%
Sales 2024 * 165M Sales 2025 * 195M Capitalization 558M
Net income 2024 * -39M Net income 2025 * -33M EV / Sales 2024 * 2.75 x
Net cash position 2024 * 103M Net cash position 2025 * 88.22M EV / Sales 2025 * 2.42 x
P/E ratio 2024 *
-14.2 x
P/E ratio 2025 *
-17.2 x
Employees 344
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.88%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.04%
1 week-5.90%
Current month-4.98%
1 month-7.00%
3 months-23.70%
6 months-26.60%
Current year-35.45%
More quotes
1 week
13.34
Extreme 13.34
14.29
1 month
13.34
Extreme 13.34
15.80
Current year
13.34
Extreme 13.34
21.64
1 year
13.34
Extreme 13.34
29.51
3 years
11.14
Extreme 11.14
34.38
5 years
7.20
Extreme 7.2
37.21
10 years
7.20
Extreme 7.2
37.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 15-05-25
Founder 69 08-03-17
Director of Finance/CFO 44 21-04-18
Members of the board TitleAgeSince
Founder 69 08-03-17
Director/Board Member 70 12-12-31
Director/Board Member 77 10-12-31
More insiders
Date Price Change Volume
24-05-28 13.68 +0.96% 97 817
24-05-24 13.55 +1.04% 209,176
24-05-23 13.41 -4.42% 375,790
24-05-22 14.03 -0.14% 377,473
24-05-21 14.05 -2.43% 269,143

Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT

More quotes
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
13.55 USD
Average target price
25.56 USD
Spread / Average Target
+88.60%
Consensus